{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:47:48Z","timestamp":1787827668108,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Irving Institute for Clinical and Translational Research Collaborative and Multidisciplinary Pilot Research Award at CUMC"},{"name":"Howard Solomon Research Fund (CUMC)"},{"name":"National Center for Advancing Translational Sciences, National Institutes of Health","award":["UL1 TR000040"],"award-info":[{"award-number":["UL1 TR000040"]}]}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.contraception.2015.09.015","type":"journal-article","created":{"date-parts":[[2015,10,17]],"date-time":"2015-10-17T05:24:45Z","timestamp":1445059485000},"page":"70-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clotting factor changes during the first cycle of oral contraceptive use"],"prefix":"10.1016","volume":"93","author":[{"given":"Carolyn L.","family":"Westhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Cremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa V.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm C.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2015.09.015_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0010-7824(97)00119-4","article-title":"First-time use of newer oral contraceptives and the risk of venous thromboembolism","volume":"56","author":"Suissa","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0010","first-page":"61","article-title":"Oral contraceptives and risk of venous thromboembolism: impact of duration of use","volume":"57","author":"Farley","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0015","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case\u2013control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.09.015_bb0020","doi-asserted-by":"crossref","first-page":"h2135","DOI":"10.1136\/bmj.h2135","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism: nested case\u2013control studies suing the QResearch and CPRD databases","volume":"350","author":"Vinogradova","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.09.015_bb0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-0037-1615216","article-title":"Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives","volume":"80","author":"Bloemenkamp","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.contraception.2015.09.015_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-7824(02)00476-6","article-title":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study","volume":"67","author":"The Oral Contraceptive and Hemostasis Study Group","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/MBC.0b013e32833b2b84","article-title":"Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy","volume":"21","author":"DeSancho","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.contraception.2015.09.015_bb0040","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2002-05-1416","article-title":"Fibrin fragment D-dimer and the risk of future venous thrombosis","volume":"101","author":"Cushman","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.contraception.2015.09.015_bb0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-149-7-200810070-00008","article-title":"Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism","volume":"149","author":"Verhovsek","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.contraception.2015.09.015_bb0050","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1055\/s-0037-1614323","article-title":"Venous thrombosis, oral contraceptives and high factor VIII levels","volume":"82","author":"Bloemenkamp","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.contraception.2015.09.015_bb0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00001721-199910000-00002","article-title":"Influence of factor VIII\/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation","volume":"10","author":"De Mitrio","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.contraception.2015.09.015_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.contraception.2015.09.015_bb0065","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2007-0026","article-title":"Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study","volume":"92","author":"Sitruk-Ware","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2015.09.015_bb0070","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.contraception.2015.09.015_bb0075","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1253\/circj.CJ-10-1051","article-title":"High plasma level of factor VIII: an important risk factor for venous thromboembolism","volume":"75","author":"Ota","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.contraception.2015.09.015_bb0080","series-title":"Consultative hemostasis and thrombosis","author":"Kitchens","year":"2013"},{"key":"10.1016\/j.contraception.2015.09.015_bb0085","series-title":"Hemostasis and thrombosis","author":"Saba","year":"2014"},{"key":"10.1016\/j.contraception.2015.09.015_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0010-7824(90)90034-S","article-title":"Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone","volume":"41","author":"van der Vange","year":"1990","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0010-7824(02)00436-5","article-title":"Effect of four different oral contraceptives on various sex hormones and serum-binding globulins","volume":"67","author":"Wiegratz","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/16.2.215","article-title":"Oral contraceptives in the United States: trends in content and potency","volume":"16","author":"Piper","year":"1987","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.contraception.2015.09.015_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2015.09.015_bb0110","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.09.015_bb0115","series-title":"Medical eligibility criteria for contraceptive use","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.contraception.2015.09.015_bb0120","series-title":"Laboratory techniques in thrombosis: a manual","author":"Jespersen","year":"1999"},{"key":"10.1016\/j.contraception.2015.09.015_bb0125","doi-asserted-by":"crossref","first-page":"614.e1","DOI":"10.1016\/j.ajog.2014.12.007","article-title":"Estimating systemic exposure to ethinyl estradiol from an oral contraceptive","volume":"212","author":"Westhoff","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.09.015_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0029-1214145","article-title":"Circadian variation within hemostasis: an underrecognized link between biology and disease?","volume":"35","author":"Montagnana","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.contraception.2015.09.015_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.contraception.2012.06.003","article-title":"Using changes in binding globulins to assess oral contraceptive compliance","volume":"87","author":"Westhoff","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0140","first-page":"482","article-title":"Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?","volume":"81","author":"Odlind","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2015.09.015_bb0145","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9378(03)00950-5","article-title":"Sex hormone-binding globulin \u2014 a surrogate marker for the prothrombotic effects of combined oral contraceptives","volume":"190","author":"van Rooijen","year":"2004","journal-title":"AJOG"},{"key":"10.1016\/j.contraception.2015.09.015_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.contraception.2008.04.004","article-title":"Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives","volume":"78","author":"Stanczyk","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0155","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2008.11.002","article-title":"Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives","volume":"79","author":"van Vliet","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.09.015_bb0160","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1538-7836.2012.04720.x","article-title":"Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives","volume":"10","author":"Raps","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.contraception.2015.09.015_bb0165","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/j.1538-7836.2012.04878.x","article-title":"Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives","volume":"10","author":"Stegeman","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.contraception.2015.09.015_bb0170","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/jth.12067","article-title":"Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal","volume":"11","author":"Kluft","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.contraception.2015.09.015_bb0175","series-title":"Exploratory data analysis","author":"Tukey","year":"1977"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782415006058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782415006058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T17:05:13Z","timestamp":1567271113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782415006058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0010782415006058"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2015.09.015","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clotting factor changes during the first cycle of oral contraceptive use","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2015.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}